This study is looking at a type of lung cancer called Non-Small Cell Lung Cancer that has spread to other parts of the body or has grown in a way that cannot be cured with surgery or radiation. Specifically, this study focuses on lung cancer that has certain changes in a gene called EGFR, which stands for epidermal growth factor receptor. These changes are known as EGFR mutations and include specific types called Ex19del and Ex21 L858R. The study will test two different treatment combinations. One group of patients will receive JNJ-61186372, which contains the active substance amivantamab, given as an injection under the skin, together with JNJ-73841937, which contains the active substance lazertinib, taken as a tablet by mouth. This combination will be used as a first treatment for patients who have not yet received other treatments for their advanced lung cancer. The other group of patients will receive JNJ-61186372 combined with platinum-based chemotherapy, which are drugs that contain platinum and are commonly used to treat cancer, and this will be given as a second treatment for patients who have already received one previous treatment.

The purpose of this study is to see how well these treatment combinations work against the lung cancer in patients who have the specific EGFR mutations. The study will look at whether the treatments can slow down or stop the cancer from growing or spreading. Patients in the study will receive their assigned treatment combination and will be monitored regularly by the doctors to check how the cancer is responding and to watch for any side effects. The study is designed as an open-label trial, which means that both the patients and the doctors will know which treatment is being given.

During the study, patients will have regular visits where doctors will perform tests and examinations to measure the size of the cancer and see if it is getting smaller, staying the same, or growing. The study will follow patients for several years to gather information about how long the treatment keeps the cancer under control and how patients feel while taking the medications. This information will help doctors understand whether these treatment combinations could be useful options for patients with this type of lung cancer in the future.